HomeCompareVMVAX vs KMB

VMVAX vs KMB: Dividend Comparison 2026

VMVAX yields 1.47% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMB wins by $24.1K in total portfolio value
10 years
VMVAX
VMVAX
● Live price
1.47%
Share price
$93.99
Annual div
$1.38
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.8K
Annual income
$161.70
Full VMVAX calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — VMVAX vs KMB

📍 KMB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMVAXKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMVAX + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMVAX pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMVAX
Annual income on $10K today (after 15% tax)
$124.95/yr
After 10yr DRIP, annual income (after tax)
$137.45/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, KMB beats the other by $4,301.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMVAX + KMB for your $10,000?

VMVAX: 50%KMB: 50%
100% KMB50/50100% VMVAX
Portfolio after 10yr
$33.9K
Annual income
$2,692.02/yr
Blended yield
7.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

VMVAX
No analyst data
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMVAX buys
0
KMB buys
0
No recent congressional trades found for VMVAX or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMVAXKMB
Forward yield1.47%5.25%
Annual dividend / share$1.38$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$21.8K$45.9K
Annual income after 10y$161.70$5,222.34
Total dividends collected$1.5K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: VMVAX vs KMB ($10,000, DRIP)

YearVMVAX PortfolioVMVAX Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$10,847$147.01$11,314$614.45$467.00KMB
2$11,755$149.02$12,867$760.19$1.1KKMB
3$12,729$150.94$14,713$945.27$2.0KKMB
4$13,773$152.75$16,924$1,181.90$3.2KKMB
5$14,891$154.46$19,596$1,486.64$4.7KKMB
6$16,090$156.08$22,850$1,882.16$6.8KKMB
7$17,374$157.61$26,849$2,399.80$9.5KKMB
8$18,749$159.05$31,812$3,083.36$13.1KKMB
9$20,222$160.41$38,033$3,994.72$17.8KKMB
10$21,799$161.70$45,918$5,222.34$24.1KKMB

VMVAX vs KMB: Complete Analysis 2026

VMVAXStock

This low-cost index fund offers exposure to mid-capitalization U.S. value stocks. Value stocks are those that may be temporarily undervalued by investors. These companies typically grow at a slower pace than the broader group of mid-sized companies. One of the fund’s key risks is that mid-capitalization stocks tend to be more volatile than large-company stocks. Investors looking to add a passively managed, mid-cap value allocation to an already diversified portfolio may wish to consider this option.

Full VMVAX Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this VMVAX vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMVAX vs SCHDVMVAX vs JEPIVMVAX vs OVMVAX vs KOVMVAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.